according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Cloprostenol (with Propylene Glycol) Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road

Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number: +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (%	
		w/w)	
4-Chloro-3-methylphenol	59-50-7	>= 0.1 - < 0.25	
Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-$	55028-72-3	< 0.1	

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.12.2024 14.04.2025 5266457-00012 Date of first issue: 14.11.2019 5.0

chlorophenoxy)-3-hydroxybut-1-enyl]-3,5dihydroxycyclopentyl]hept-5-enoate

4. FIRST AID MEASURES

In case of skin contact

If inhaled If inhaled, remove to fresh air.

> Get medical attention if symptoms occur. Wash with water and soap as a precaution.

Get medical attention if symptoms occur. Flush eyes with water as a precaution. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

> Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delaved

Protection of first-aiders

None known.

No special precautions are necessary for first aid responders.

Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Notes to physician

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage

Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
4-Chloro-3-methylphenol	59-50-7	TWA	200 μg/m3 (OEB	Internal
			2)	
		Wipe limit	100 μg/100 cm2	Internal
Sodium	55028-72-3	TWA	0.01 ug/m3 (OEB	Internal
$[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-$			5)	

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

7-[2-[4-(3-chlorophenoxy)-3- hydroxybut-1-enyl]-3,5- dihydroxycyclopentyl]hept-5- enoate						
	Further information: RSEN, Skin					
		Wipe limit	0.1 ug/100 cm2	Internal		

Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type
Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Colour : colourless

Odour : characteristic

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : -6 °C

Initial boiling point and boiling :

range

99 °C

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : 1.02 - 1.08

Density : No data available

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : 1.56 - 1.62 mm2/s

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : Can react with strong oxidizing agents.

ions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Inhalation exposure Skin contact

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Acute oral toxicity : LD50 (Mouse): 600 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 2.871 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 14.04.2025 5266457-00012 Date of first issue: 14.11.2019 5.0

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5$ dihydroxycyclopentyl]hept-5-enoate:

: LD50 (Rat): > 25 mg/kg Acute oral toxicity

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of : LD50 (Rat): > 50 mg/kg

administration)

Application Route: Subcutaneous

LD50 (Rat): > 50 mg/kg

Application Route: Intramuscular

LD50 (Rat): 5 mg/kg

Application Route: Intravenous

Remarks: No mortality observed at this dose.

LD50 (Mouse): 350 mg/kg Application Route: Intramuscular

LD50 (Mouse): 54.7 mg/kg Application Route: Intravenous

TDLo (Monkey): 0.0025 - 0.025 mg/kg Application Route: Intramuscular

Target Organs: Lungs

Symptoms: Diarrhoea, Vomiting, Rapid respiration

TDLo (Monkey): 0.0013 mg/kg Application Route: Intramuscular

Target Organs: ovaries

Skin corrosion/irritation

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Species Rabbit

Method **OECD Test Guideline 404**

Result Corrosive after 1 to 4 hours of exposure

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5$ dihydroxycyclopentyl]hept-5-enoate:

Remarks Not classified due to lack of data.

Can be absorbed through skin.

Serious eye damage/eye irritation

Not classified based on available information.

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

Components:

4-Chloro-3-methylphenol:

Species : Rabbit

Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Remarks : Not classified due to lack of data.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig

Assessment : Probability or evidence of low to moderate skin sensitisation

rate in humans

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Result : Sensitiser

Germ cell mutagenicity

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: equivocal

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Cell type: Bone marrow

Application Route: Intraperitoneal

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Remarks : Not classified due to lack of data.

Reproductive toxicity

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion

Result: negative

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Effects on fertility : Test Type: Three-generation study

Species: Rat

Application Route: Oral

General Toxicity F1: NOAEL: 0.015 mg/kg body weight

Fertility: NOAEL: > 0.04 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Species: Cattle

Application Route: Intramuscular

General Toxicity - Parent: LOAEL: 0.16 µg/kg

Result: positive

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

Remarks: Abortion

Effects on foetal develop- : Test Type: Development

ment Species: Rabbit

Application Route: Subcutaneous Teratogenicity: NOAEL: 0.250 µg/kg Result: No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Oral

Teratogenicity: NOAEL: 100 μg/kg Result: No teratogenic effects

Reproductive toxicity - As-

sessment

May damage fertility.

STOT - single exposure

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Assessment : May cause respiratory irritation.

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Target Organs : Lungs

Assessment : Causes damage to organs.

STOT - repeated exposure

Not classified based on available information.

Components:

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Target Organs : Ovary

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

4-Chloro-3-methylphenol:

Species : Rat

NOAEL : 200 mg/kg

LOAEL : 400 mg/kg

Application Route : Ingestion

Exposure time : 28 Days

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Species : Rat

NOAEL : 0.05 mg/kg LOAEL : 0.15 mg/kg Application Route : Oral

Exposure time : 3 Months
Target Organs : Ovary

Species : Rat

LOAEL : 0.0125 mg/kg
Application Route : Subcutaneous
Exposure time : 30 Days
Target Organs : Ovary

Species: MonkeyNOAEL: 0.05 mg/kgLOAEL: 0.15 mg/kgApplication Route: OralExposure time: 3 MonthsTarget Organs: Heart, Testis

Aspiration toxicity

Not classified based on available information.

Components:

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

Not applicable

Experience with human exposure

Components:

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:$

General Information : Target Organs: Uterus (including cervix)

Symptoms: Embryo-foetal toxicity, foetal mortality, menstrual

irregularities, miscarriage Target Organs: Lungs

Symptoms: Asthma, bronchospasm

Inhalation : Target Organs: Lungs

Symptoms: bronchospasm, Asthma

Remarks: May cause sensitisation of susceptible persons by

inhalation of aerosol or dust.

Target Organs: Uterus (including cervix)

Symptoms: Embryolethal effects, menstrual irregularities

Skin contact : Target Organs: Lungs

Symptoms: bronchospasm

Remarks: Can be absorbed through skin. Target Organs: Uterus (including cervix)

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 14.04.2025 5266457-00012 Date of first issue: 14.11.2019 5.0

П Symptoms: Embryolethal effects

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

4-Chloro-3-methylphenol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 917 µg/l

Exposure time: 96 h

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 1.5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

: ErC50 (Chlorella pyrenoidosa (algae)): 15 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC10 (Chlorella pyrenoidosa (algae)): 2.3 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- : 1

Toxicity to microorganisms : EC50: 22.86 mg/l

Exposure time: 60 h

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.32 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Sodium $[1\alpha(Z),2\beta(1E,3R^*),3\alpha,5\alpha]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5$ dihydroxycyclopentyl]hept-5-enoate:

Ecotoxicology Assessment

Acute aquatic toxicity Toxic effects cannot be excluded

Chronic aquatic toxicity Toxic effects cannot be excluded

Persistence and degradability

Components:

4-Chloro-3-methylphenol:

Result: Readily biodegradable. Biodegradability

> Biodegradation: 78 % Exposure time: 15 d

Method: OECD Test Guideline 301

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

Version Revision Date: SDS Number: Date of last issue: 04.12.2024 5.0 14.04.2025 5266457-00012 Date of first issue: 14.11.2019

П

Bioaccumulative potential

Components:

4-Chloro-3-methylphenol:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 5.5 - 13

Partition coefficient: n-

octanol/water

: log Pow: 0.477

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 5.0
 14.04.2025
 5266457-00012
 Date of first issue: 14.11.2019

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 14.04.2025

Further information

Sources of key data used to compile the Safety Data

Sheet Safety Data eCnem Port cy, http://ech

eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Internal technical data, data from raw material SDSs, OECD

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant: DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

according to the Globally Harmonized System



Cloprostenol (with Propylene Glycol) Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.12.2024

 5.0
 14.04.2025
 5266457-00012
 Date of first issue: 14.11.2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN